BMC Infectious Diseases

, 14:561 | Cite as

Visceral leishmaniasis due to Leishmania infantumwith renal involvement in HIV-infected patients

  • Matteo Vassallo
  • Olivier Moranne
  • Damien Ambrosetti
  • Pierre-Yves Jeandel
  • Christelle Pomares
  • Elisabeth Cassuto
  • Annick Boscagli
  • Guillaume Giraud
  • Nathalie Montagne
  • Chiara Dentone
  • Ilaria Demacina
  • Barbara Villaggio
  • Giovanni Secondo
  • Giuseppe Ferrea
  • Corinne Passeron
  • Laurence Saudes
  • Regis Kaphan
  • Pierre Marty
  • Eric Rosenthal
Open Access
Case report
Part of the following topical collections:
  1. HIV and co-infections

Abstract

Background

We describe histological, clinical findings and outcomes of renal involvement during Leishmania infantum infection in four HIV-infected patients in South France and North Italy hospital settings.

Cases presentation

Four HIV-infected Caucasian patients (age 24-49) performed renal biopsy during episodes of visceral leishmaniasis. They presented severe immunosuppression, frequent relapses of visceral leishmaniasis during a follow-up period of several years and partial or complete recovery of renal function after anti-parasitic treatment. Main clinical presentations were nephrotic or nephritic syndrome and/or acute renal failure secondary to membranoproliferative type III glomerulonephritis or acute interstitial nephritis. Clinical outcome was poor, probably as a consequence of insufficient immuno-virological control of the HIV infection.

Conclusions

Our findings suggest that the main histological findings in case of renal involvement due to Leishmania infantum infection in HIV-infected patients are type III MPGN and acute interstitial nephritis, with a histological specificity similar to that observed in canine leishmaniasis. Poor immune status in HIV-infected patients, altering the capacity for parasite clearance, and prolonged course of chronic active VL in this population may lead to the development of specific renal lesions.

Keywords

Visceral Leishmaniasis Renal Involvement Darunavir Secondary Prophylaxis Etravirine 

Background

Leishmaniasis due to Leishmania infantum is a vector-borne disease which is endemic in Southern Europe [1]-[5]. In humans, Leishmania infection gives rise to a range of presentations (mainly visceral, cutaneous and mucosal) depending on the species involved and the effectiveness of the patient’s immune response to the parasite [2],[6],[7]. Visceral leishmaniasis (VL) is present in 61 countries across 4 continents where 200 million people are exposed. Approximately 0.2 to 0.4 million cases of VL and 0.7 to 1.2 million cases of cutaneous leishmaniasis occur each year, with 5 countries (India, Nepal, Bangladesh, Sudan, Brazil) accounting for 90% of these, whereas the condition remains sporadic in Southern Europe [1]-[4]. In immunosuppressed individuals, including HIV-infected patients, the clinical presentation of VL can be atypical [8], easily misdiagnosed or mistaken as a flare-up of the underlying disease. Before the introduction of combination antiretroviral therapy (cART), the incidence of VL was higher in HIV-infected patients than in immunocompetent subjects, with higher rates of relapse and mortality [2]. In the cART era, the incidence of VL in the HIV-infected population has dramatically decreased [9]-[13]. Moreover, with the longer life expectancy of HIV-infected individuals, new clinical features of VL have been reported, such as active chronic VL, characterized by relapses over a period of several years and continuous circulation of the parasite in the bloodstream [14].

Renal involvement in HIV-infected patients with VL is uncommon and few cases have been reported [15]-[19]. Patients displayed various patterns of clinical and histological presentation: isolated proteinuria or hematuria, nephrotic syndrome (proteinuria >2.5 g/day, hypoalbuminemia and generalized oedema), nephritic syndrome (glomerular proteinuria & hematuria, reduced glomerular filtration rate with varying degrees of azotemia, oliguria and hypertension) secondary to membrano-proliferative glomerulonephritis (MPGN) or amyloidosis, and acute kidney injury (AKI) secondary to interstitial nephritis [15]-[22].

We present a series of four cases of VL due to Leishmania infantum with renal involvement in HIV-infected patients, including histological findings and clinical outcome. Patients were hospitalized between 1996 and 2012 in Infectious Diseases Hospital departments in the Alpes-Maritimes, France and in Liguria, Italy, where Leishmania infantum infection is endemic.

Cases presentation

Case report n° 1

A 40-year-old HIV-infected male patient, born and residing in the Nice area (Alpes-Maritimes, South-Eastern France), was admitted to hospital in June 2011 for persistent diarrhoea and weight loss (5 kgs). He had contracted HIV-infection in 1996, and his previous medical history included VL in 2000, (with clinical relapses in 2005 and 2009 but no renal involvement), high blood pressure, cerebral toxoplasmosis and Kaposi’s sarcoma in 2003, and pneumocystis pneumonia in 2006. His antiretroviral regimen included etravirine, darunavir and ritonavir. The latest CD4 cell count was 114 cells/mm3 (nadir: 46 cells/mm3) and HIV viral load was 162 copies/ml. Compliance with cART had frequently been sub-optimal. He presented with nephritic syndrome, urine dipstick analysis revealing proteinuria and hematuria, but no leukocyturia. Blood pressure was 150/100 mmHg, with peripheral œdema. All kidney tissue samples were obtained via needle biopsy. Light microscopy examination showed diffuse hyper-cellularity with thickening of the glomerular basement membrane, and immunofluorescence microscopy revealed IgG, IgM, C3 and C1q mesangial and endo-membranous deposits . According to the World Health Organisation (WHO) classification, the histological findings were typical of type III membrano-proliferative glomerulonephritis (MPGN).

Diagnosis of VL was based on molecular methods using Leishmania infantum polymerase chain reaction (PCR) (Taqman technology; Light Cycler target: kinetoplast mini-circle DNA) on peripheral blood and other biological samples, i.e. bone marrow, urine and kidney [23]. In this patient, qualitative PCR was positive in both urine and peripheral blood. VL relapse was suspected and liposomal Amphotericine B (l-Ampho-B), 3 mg/kg daily, initially scheduled for 10 days, was prematurely discontinued due to deteriorating renal function and suspected drug-associated tubulopathy. The patient’s condition gradually improved and secondary VL prophylaxis consisting in monthly intravenous pentamidine infusions was initiated. During follow-up, creatinine levels remained stable and viro-immunological parameters improved. The patient was re-admitted in October 2013 for another relapse of VL. Poor cART compliance was suspected. The CD4 T-cell count and plasma HIV-RNA level were 79 cells/mm3 and 1,500 copies/ml, respectively. PCR was positive for Leishmania infantum with 992 parasites/ml in plasma and 322 parasites/106 cells in bone marrow. Treatment with l-Ampho-B was started, adapting dosage to renal function; fever resolved, parasitemia dropped to 312 parasites/ml and the estimated glomerular filtration rate (eGFR) remained stable. Antiretroviral treatment was switched from a twice-daily to a once-daily regimen, in order to improve compliance. The patient was discharged and continued secondary VL prophylaxis as an outpatient with L-Ampho-B.

Table 1 summarizes baseline characteristics, renal impairment and clinical outcome for all four patients, while the main histological findings are described in Table 2.
Table 1

Description of cases of VL with renal injury and outcome

 

Case 1

Case 2

Case 3

Case 4

Clinical characteristics

    

Age

40

35

24

49

Years since HIV contamination

15

11

24

16

Years since diagnosis of visceral Leishmaniosis

11

9

2

19

Renal syndrome

Nephritic syndrome

Nephrotic syndrome

AKI

Nephrotic syndrome

Biology

    

Leishmania quantitative PCR test (parasites/ml)

6225 (blood)

1700000 (kidney)

Not available

11570 (blood)

C4 concentration (normal range 0.14-0.33 g/l)

0.12

Not available

0.14

0.2

Cryoglobulin

Positive

Not available

Positive

Positive type 2

HCV serology

Negative

Negative

Negative

Positive

HCV viral load in blood (qualitative)

-

-

-

Negative

Serum albumin (g/l) at time of diagnosis or during follow-up

25

22/14

-

20/24

Plasma hyper-gammaglobulinemia

Yes

Unknown

Yes

Yes

Platelets >150000 giga/L at time of renal biopsy

Yes

Yes

Yes

Yes

Severe clottingdysfunction

No

No

No

No

Hepatic function

Normal

Normal

Normal

Normal

HIV viral load (copies/ml)

162

41000

2000

< 40

CD4 T-cell count (cells/mm 3 )

114

12

70

84

CD4 T-cell nadir (cells/mm 3 )

46

12

50

84

Plasma creatinine concentrations (year, [μmol/l]) diagnosis/follow-up

143/152

2006 (100)/2007 (265)/2008(488)

154 / 99

55 / 60

CKD-EPI (ml/min/1.73 m 2 ) diagnosis/follow-up

48/47

105 / 90 / 52

 

69

Urinalysis

    

Daily proteinuria (g/day) Diagnosis/follow-up

2.1

1.5/2.0/3.0

0.3 / 0.5

2.0 / 0.5

Hematuria/Leukocyturia

+/-

+/-

-/+

-/-

Kidney histological findings

MPGN III

MPGN III and Interstitial nephropathy

Interstitial nephropathy

MPGN III and interstitial nephropathy

Treatment and outcome

    

VL treatment regimen

l-Amph-B, Pentamidine

l-Amph-B, Pentamidine,

l-Amph-B

l-Amph-B, Miltéfosime

  

Miltefosine

  

Renal outcome

Improved

Not improved

Improved

Improved but worsened at clinical relapse

Patient outcome

Partial recovery

Died

Partial recovery

Died

VL: Visceral Leishmaniasis.

PCR: Polymerase Chain Reaction.

CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration Equation.

l-Amph-B: liposomal Amphotericine B.

Table 2

Description of kidney histo-pathological diagnosis

Patient

Case 1

Case 2

Case 3

Case 4

Renal histology

MPGN type III

MPGN type III

Acute interstitial nephritis

MPGN type III

Light microscopy

Diffuse hypercellularity and thickening of glomerular basement membrane.

Subendothelial and subepithelial deposits with mesangial interposition associated with basement membrane spikes

Acute interstitial nephritis: edema associated with interstitial lymphoplasmocytic infiltration in addition to mild tubulointerstitial fibrosis.

Subendothelial and subepithelial deposits and mesangial interposition associated with basement membrane spikes.

Free Leishmania in a capillary lumen

Tubules are invaded by lymphocytes and areas of necrosis are visualized.

Interstitial granuloma. Positive PCR for Leishmania infantum in urine and in renal biopsy

Positive PCR for Leishmania infantum in the renal biopsy

Glomeruli are uninvolved. Free Leishmania in a capillary lumen

Immunofluorescence

Mesangial and endomembranous deposits of IgG, IgM, C3 and C1q

Fine granular deposition of IgG and C3 in the mesangium and along the peripheral capillary loops

Deposits of IgG and IgM with a mesangial pattern

Mesangial and endomembranous deposits of IgG and C3

MPGN: Membrano-proliferative glomeruolonephritis.

PCR: Polymerase Chain Reaction.

Case report n° 2

A 35-year-old male patient, HIV-infected since 1997, born and residing in the Nice area (Alpes-Maritimes, South-Eastern France), was first admitted to hospital in 1998 with VL. He was treated with l-Ampho-B and symptoms improved. During the following years, the patient had several relapses of VL despite various secondary prophylaxis regimens, including l-ampho-B, pentamidine and miltefosine. In 2004 he was re-admitted with suspected clinical relapse of VL. His CD4 cell count was 20 cells/mm3 while HIV viral load exceeded 100,000 copies/ml. Leishmania infantum parasites were found both in colon biopsy samples and in peripheral blood. Moreover, liver biopsy showed large macrophages containing Leishmania infantum. An additional course of l-Ampho-B resulted in clinical recovery and was followed by maintenance therapy. The eGFR was normal. Compliance with cART was poor and the CD4 T-cell count remained below 200 cells/mm3.

In 2006 the patient presented with nephrotic syndrome. C4 and C3 concentrations were normal, while HIV viral load and CD4 T-cell count were 41,000 copies/ml and 12 cells/mm3, respectively. Leishmania amastigotes were observed on a blood smear. A renewed course of l-ampho-B resulted in remission of the nephrotic syndrome.

In 2007, the patient was admitted again with œdema, a weight gain of 4 kgs and dyspnœa. He presented this time with nephritic syndrome and acute kidney injury. Complement activity was normal. Gastroscopy and colonoscopy revealed several parasites in the stomach, duodenum and colon. Qualitative Leishmania infantum PCR on blood and gut samples was positive. Histological examination of kidney tissue showed type III MPGN with free Leishmania parasites in a capillary lumen (Figure 1A,B,C,D). Moreover, Leishmania infantum PCR was positive on the biopsy sample.
Figure 1

Main histological findings in patient 2, who had type III membrano-proliferative glomerulonephritis (MPGN). A. Cortical kidney inflammation (PAS x1000). B. Clusters of circulating Leishmania free parasytes in capillary (arrow) (Trichrome stain x1000). C. Prominent double contour formations (arrow) (Silver stain x1000). D. Basement membrane spikes (Silver stain x1000).

Compliance with antiretroviral treatment remained poor and in 2008 the patient was admitted to hospital for the fourth time due to renewed relapse with diarrhœa, weight loss and œdema. His HIV-RNA and CD4 T-cell count were 74,000 copies/ml and 200 cells/mm3, respectively. The patient died due to renal failure despite anti-parasitic treatment with l-Ampho-B.

Case report n° 3

A 24 year-old female patient, born in Italy and a resident of the Sanremo area (Liguria, North-Western Italy), HIV-infected via maternal-fœtal transmission, was admitted to hospital in 2012 for weight loss and AKI.

At the time of admission, her cART regimen consisted in etravine, raltegravir and boosted darunavir. The CD4 T-cell count was low (70 cells/mm3) and plasma HIV-RNA numbered2,000 copies/ml. Previous personal medical history included pneumocystis pneumonia, œsophageal candidiasis, cytomegalovirus retinitis and, more recently, two episodes of VL over the last two years. Both episodes were treated with l-Ampho-B followed by secondary prophylaxis. Several antiretroviral regimens had been administered, but compliance had never been satisfactory, viral load had been undetectable during only a few months and the CD4 T-cell count had consistently remained below 200 cells/mm3, with a nadir of 50 cells/mm3. Gastric and lymph node biopsy revealed Leishmania infantum, and a renal needle biopsy was performed to investigate AKI associated with proteinuria. Light microscopy examination showed interstitial nephritis with free Leishmania in interstitial tissue while no involvement of the glomeruli was observed. Immunofluorescence microscopy revealed a mesangial pattern of IgG and IgM deposits (Figure 2A,B)
Figure 2

Main histological results in patient 3, who presented acute interstitial nephritis without glomerular involvement. A. Acute interstitial nephritis: oedema associated with an infiltration of interstitial lymphoplasmacytoid cells (Arrowhead). Tubules are invaded by lymphocytes (Arrow). Glomeruli are uninvolved. (PAS x200). B. Free Leishmania in interstitial tissue (PAS x1000).

Treatment with l-Ampho-B was started and resulted in improved eGFR. Antiretroviral treatment was modified according to genotyping results. The patient was discharged and secondary prophylaxis with l-Ampho-B was continued. A recent outpatient follow-up visit showed stable renal function, normal urinary sediment microscopy and proteinuria of 0.53 g/24 hrs. Despite the persistent clinical relapse-free period, PCR remained positive on blood (736 parasites/ml) with a CD4 T-cell count below 200 cells/mm3 while the HIV viral load did not exceed50 copies/ml.

Case report n° 4

A 49-year-old male patient, born and residing in the Nice area (Alpes-Maritimes, South-Eastern France), HIV and hepatitis C (HCV) co-infected since the age of 16, was admitted to hospital in 2011 for weight loss, œdema and nephrotic syndrome without hematuria. The eGFR was normal. VL had been previously diagnosed in 1991 and treated, resulting in symptom resolution.

Laboratory tests upon admission showed undetectable HCV and HIV viral loads, and a CD4 T-cell count of 84 cells/mm3. The antiretroviral regimen included abacavir, lamivudine and lopinavir/ritonavir.

Antiparasitic treatment with miltefosine was initiated, resulting in clinical and biological improvement. Leishmania infantum PCR on blood was negative, but was positive on urine. Kidney histological findings showed type III MPGN and interstitial granuloma. with positive Leishmania infantum PCR on kidney tissue (Figure 3A,B). Although HCV co-infection may also cause renal injury, the undetectable HCV viral load and positive Leishmania infantum PCR suggested that MPGN was more likely to be linked to VL than to HCV. One year later, the patient was re-admitted due to clinical relapse of VL. HIV-RNA on admission was 1,700 copies/ml and CD4 T-cells numbered 78/mm3. Leishmania infantum PCR on blood was positive (11,570 parasites/ml). In spite of treatment with l-Ampho-B, the patient died a few days after admission due to severe intestinal bleeding.
Figure 3

Description of renal biopsy results for patient 4, who presented type III MPGN. A. Inflammation within the cortical kidney (PAS x100). B. Giant cell granuloma. (HE stain x 400).

Discussion

We describe four cases of VL due to Leishmania infantum in HIV-infected patients in the cART era, with specific PCR or microscopic proof of renal involvement.

All patients had severe immunosuppression, and had presented with recurring episodes of clinical relapse of VL over a follow-up period of several years. Moreover, they had partial or complete recovery of renal function after anti-parasitic treatment associated with better control of HIV infection. The main clinical presentations included nephrotic or nephritic syndrome secondary to type III MPGN or acute kidney injury secondary to interstitial nephritis.

According to the WHO classification, based on ultrastructural alterations in the glomerular basement membrane, MPGN is subdivided into 3 categories: type I (sub-endothelial deposits), type II (intra-membranous dense deposits) and type III, where deposits are found in the sub-endothelial and mesangial region, similarly to type I, but, in addition, with numerous sub-epithelial deposits [24]. Histological findings reported in our series are in line with sporadic cases described in humans and in studies on dogs, where type III MPGN was the most commonpattern [15]-[22],[25],[26]. Interestingly, free Leishmania were observed inside the capillary lumen of two patients.

MPGN during VL is probably the result of immune complex deposition occurring during chronic infection [15],[24],[27]. However, other mechanisms of injury have been suggested in dogs: indeed, there is growing evidence that T-cell migration into the glomeruli and adhesion molecules play a fundamental role in the pathogenesis of certain immunologically-mediated cases of glomerulonephritis [27]. Costa et al.[27] found considerably higher numbers of CD4 T-cells in dogs with VL compared to uninfected animals, with no relevant associated immune complex deposition. The number of T-cells was correlated to the quantity of Leishmania antigen in phagocytic cells, suggesting that the parasite itself could directly drive the inflammatory infiltrate in the glomeruli. Enhanced expression of adhesion molecules, such as P-selectin and ICAM-1, has also been found in the mesangium and glomerular capillaries of animals and humans with VL, thus suggesting that newly migrated platelets could play a role in the pathogenesis of renal injury. Finally, diminished apoptosis may be another possible mechanism contributing to the persistence and progression of glomerular hyper-cellularity [27].

Acute interstitial nephritis was the other presentation of renal involvement secondary to Leishmania infantum infection reported in this series. This is probably the result of parasitic dissemination, as reported by other authors in a human kidney transplant recipient [19] and in dogs [25],[26]. Tubular necrosis could be secondary to ischemia due to small vessel obliteration by Leishmania spp., while haemolysis and necrotizing tubulitis could be a consequence of parasitic invasion and inflammatory response [28],[29].

The correlation between immunosuppression and clinical relapse of VL has been suggested by Bourgeois et al., who showed that the persistence of CD4 T-cell counts <100 cells/mm3 is one of the main risk factors for relapse [30]. Since the advent of cART, features of HIV/Leishmania spp. coinfection include a chronic course of parasitic disease with latent parasitemia and a high rate of relapse. Bourgeois et al.[14] defined the condition as “active chronic VL”, where patients have long-term persistence of circulating Leishmania species with alternating symptomatic and asymptomatic phases. As showed by Kubar et al. [31], patients with relapsing VL generally have lower CD4 T-cell counts than HIV-infected patients with primary VL, suggesting that in addition to the T-cell-mediated response, essential at the time of primary Leishmania infection, supplementary mechanisms might operate in case of chronic infection.

Patients described in this series received various antiparasitic agents including l-Ampho-B, pentamidine and miltefosine. They all responded, at least partially, but they sufferedseveral relapses despite secondary prophylaxis. Data regarding secondary prophylaxis of VL in HIV-infected patients are scarce, explaining the absence of guidelines favouring a particular regimen [32]. There is no consensus on the management of active chronic VL. It is currently suggested that parasite detection by PCR, together with CD4 T-cell count, may guide decisions for prolonging or stopping prophylaxis in HIV-infected patients [33]-[36]. Bourgeois et al. suggest that secondary prophylaxis could be discontinued in patients taking cART when either 1) PCR remains negative for at least 6 months and CD4 T-cell count is >200 cells/mm3 or 2) CD4 T-cell count is <200 cells/mm3 but PCR remains negative for at least 18 months [30].

This case series showed that the clinical outcome of VL and renal injury is associated with viro-immunological control of HIV infection, suggesting that immune restoration plays a pivotal role in preventing relapse. In this case series, suboptimal compliance with antiretroviral treatment was probably the main cause of poor immune recovery, as proven by frequent episodes of viral replication during follow-up. However, VL itself might play a role: Leishmania co-infection could enhance viral replication and immune activation, thus contributing to CD4 T-cell depletion and increasing the risk of reactivation of latent infections [37],[38]. Thus, even patients with successful antiretroviral treatment could be at risk for Leishmania re-activation.

Finally, in this series, patients presented with active chronic VL progressing over a protracted course, ranging from 2 to 19 years (median 8 yrs). In mixed cryoglobulinemia due to hepatitis C virus, another condition mediated by immune complex deposition, vasculitis-related symptoms, including renal involvement, are associated with longer duration of HCV infection [39]. Similarly, in active chronic VL, prolonged infection may be required to develop renal disease.

Conclusions

Our results suggest that the main histological findings in case of renal involvement due to Leishmania infantum infection in HIV-infected patients are type III MPGN and acute interstitial nephritis, with specific histological features similar to those observed in canine leishmaniasis. Poor immune status in HIV-infected patients, altering the capacity for parasite clearance, and prolonged course of chronic active VL in this population may lead to the development of these specific renal lesions. These patients should thus be regularly screened for Leishmania infantum infection and their renal function closely monitored.

Consent

Written informed consent was obtained from patients for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Notes

Acknowledgments

We thank all patients for accepting to participate in the collection of data.

We also wish to thank Julie Medway for paper revision.

Supplementary material

12879_2014_561_MOESM1_ESM.gif (177 kb)
Authors’ original file for figure 1
12879_2014_561_MOESM2_ESM.gif (108 kb)
Authors’ original file for figure 2
12879_2014_561_MOESM3_ESM.gif (119 kb)
Authors’ original file for figure 3

References

  1. 1.
    Berman JD: Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997, 24 (Suppl 4): 684-703. 10.1093/clind/24.4.684.CrossRefPubMedGoogle Scholar
  2. 2.
    Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, Molina R, Moreno J: Leishmania and human immunodeficiency virus co-infection: the first 10 years. J Clin Microbiol Rev. 1997, 10: 298-319.Google Scholar
  3. 3.
    Oliveira CMC, Oliveira MLMB, Andrade SCA, Girao CS, Ponte CN, Mota MU, Fernandes PFCBC, Campos HH, Esmeraldo RM, Evangelista JB: Visceral leishmaniasis in renal transplant recipients: clinical aspects, diagnostic problems, and response to treatment. Transplant Proc. 2008, 40 (Suppl 3): 755-760. 10.1016/j.transproceed.2008.02.039.CrossRefPubMedGoogle Scholar
  4. 4.
    Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, Den Boer M: Leishmaniasis worldwide and global estimates of its incidence. Plos One. 2012, 7 (suppl. 5): e35671-10.1371/journal.pone.0035671.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pérez-Molina JA, López V, Guerrero A: Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals. Am J Med. 1997, 102 (Suppl 1): 132-PubMedGoogle Scholar
  6. 6.
    Herwaldt BL: Leishmaniasis. Lancet. 1999, 354: 1191-1199. 10.1016/S0140-6736(98)10178-2.CrossRefPubMedGoogle Scholar
  7. 7.
    Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J: The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008, 21 (Suppl 2): 334-359. 10.1128/CMR.00061-07.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rosenthal E, Marty P, Poizot M, Reynes J, Platlong F, Lafeuillade A, Jaubert D, Boulat O, Dereure G, Gamabarelli A: Visceral leishmaniasis and HIV-1 co-infection in Southern France. Trans R Soc Trop Med Hyg. 1995, 89: 159-162. 10.1016/0035-9203(95)90476-X.CrossRefPubMedGoogle Scholar
  9. 9.
    Rosenthal E, Tempesta S, Del Giudice P, Marty P, Desjeux P, Pradier C, Le Fichoux Y, Cassuto JP: Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS. 2001, 15: 1884-1885. 10.1097/00002030-200106150-00017.CrossRefGoogle Scholar
  10. 10.
    Rybniker J, Goede V, Mertens J, Ortmann M, Kulas W, Kochanek M, Benzing T, Arribas JR, Fatkenheuer G: Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure-a case report and brief review of the literature. Int J Infect Dis. 2010, 14: 522-525. 10.1016/j.ijid.2009.06.010.CrossRefGoogle Scholar
  11. 11.
    Dujardin JC, Campino L, Cañavate C, Dedet JP, Gradoni L, Soteriadou K, Mazeris A, Ozbel Y, Boelaert M: Spread of vector-borne diseases and neglect of Leishmaniasis. Europe Emerg Infect Dis. 2008, 14 (Suppl 7): 1013-1018. 10.3201/eid1407.071589.CrossRefPubMedGoogle Scholar
  12. 12.
    Rosenthal E, Marty P: Leishmaniose viscérale. Rev Prat. 2004, 54 (Suppl 20): 2211-2216.PubMedGoogle Scholar
  13. 13.
    Del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D, Rosenthal E: Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a french cohort of patients infected with human immunodeficiency virus. J Infect Dis. 2002, 186: 1366-1370. 10.1086/344325.CrossRefPubMedGoogle Scholar
  14. 14.
    Bourgeois N, Bastien P, Reynes J, Makinson A, Rounet I, Lachaud L: Active chronic visceral leishmaniasis” in HIV-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med. 2010, 11 (Suppl 10): 670-673. 10.1111/j.1468-1293.2010.00846.x.CrossRefPubMedGoogle Scholar
  15. 15.
    Amann K, Bogdan C, Harrer T, Rech J: Renal leishmaniasis as unusual cause of nephrotic syndrome in an HIV patient. J Am Soc Nephrol. 2012, 23: 586-590. 10.1681/ASN.2011050472.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Davidson RN: Practical guide for the treatment of leishmaniasis. Drugs. 1998, 56: 1009-1018. 10.2165/00003495-199856060-00005.CrossRefPubMedGoogle Scholar
  17. 17.
    Suankrantay C, Suwanpimolkul G, Wilde H, Siriyasatien P: Case report: Autochtonus visceral leishmaniasis in a human immunodeficiency virus (HIV)-infected patient: the first in Thailand and review of the literature. Am J Trop Med Hyg. 2010, 82 (Suppl 1): 4-8. 10.4269/ajtmh.2010.09-0434.CrossRefGoogle Scholar
  18. 18.
    Jarvis JN, Lockwood DN: Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis. 2013, 26: 1-9. 10.1097/QCO.0b013e32835c2198.CrossRefPubMedGoogle Scholar
  19. 19.
    Dettwiler S, McKee T, Hadaya K, Chappuis F, van Deiden C, Moll S: Visceral Leishmaniasis in a kidney transplant recipient: parasitic interstitial nephritis, a cause of renal dysfunction. Am J Transplant. 2010, 10: 1486-1489. 10.1111/j.1600-6143.2010.03125.x.CrossRefPubMedGoogle Scholar
  20. 20.
    Alex S, Criado C, Fernandez-Guerrero ML, de Gorgolas M, Petkov V, Garcia Perez A, Egido J, Barat A, Manzarbeitia F, Carmelo C, Ortiz A: Nephrotic syndrome complicating chronic visceral leishmaniasis: re-emergence in patients with AIDS. Clin Nephrol. 2008, 70 (Suppl 1): 65-68.PubMedGoogle Scholar
  21. 21.
    Clevenbergh P, Nkoumou Okome M, Benoit S, Bendini JC, De Salvador F, Elbeze M, Cassuto E, Marty P, Dellamonica P: Acute renal failure as initial presentation of visceral leishmaniasis in an HIV-1 infected patient. Scand J Infect Dis. 2002, 34 (Suppl 7): 546-547. 10.1080/003655402320208857.CrossRefPubMedGoogle Scholar
  22. 22.
    Daher EF, Rocha NA, Oliveira MJ, Franco LF, Oliveira JL, Silva Junior GB, Abreu KL, Henn GA, Martins AM, Libório AB: Renal function improvement with pentavalent antimonial agents in patients with visceral leishmaniasis. Am J Nephrol. 2011, 33 (Suppl 4): 332-336. 10.1159/000324914.CrossRefPubMedGoogle Scholar
  23. 23.
    Mary C, Faraut F, Lascombe L, Dumon H: Quantification of Leishmania infantum DNA by a real-time PCR assay with sensitivity. J Clin Microbiol. 2004, 42: 5249-5255. 10.1128/JCM.42.11.5249-5255.2004.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Aresu L, Valenza F, Ferroglio E, Pregel P, Uslenghi F, Tarducci A, Zanatta R: Membranoproliferative glomerulonephritis type III in a simultaneous infection of Leishmania infantum and Dirofilaria immitis in a dog. J Vet Diagn Invest. 2007, 19 (Suppl 5): 569-572. 10.1177/104063870701900520.CrossRefPubMedGoogle Scholar
  25. 25.
    Rollino C, Bellis D, Beltrame G, Basolo B, Montemagno A, Bucolo S, Ferro M, Quattrocchio G, Coverlizza S, Quarello F: Acute renal failure in leishmaniasis. Nephrol Dial Transplant. 2003, 18: 1950-1951. 10.1093/ndt/gfg267.CrossRefPubMedGoogle Scholar
  26. 26.
    Poli A, Abramo F, Mancianti F, Nigro M, Pieri S, Bionda A: Renal involvement in canine leishmaniasis: a light-microscopic, immunohistochemical and electron-microscopic study. Nephron. 1991, 57: 444-452. 10.1159/000186348.CrossRefPubMedGoogle Scholar
  27. 27.
    Costa FAL, Prianti MG, Silva TC, Silva SMMS, Guerra JL, Goto H: T cells, adhesion molecules and modulation of apoptosis in visceral leishmaniasis glomerulonephritis. BMC Infect Dis. 2010, 10: 112-10.1186/1471-2334-10-112.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Clerici M, Hakim FTD, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, Shearer GM: Changes in interleukine 2 and interleukine 4 in asymptomatic human immunodeficiency virus seropositive individuals. J Clin Invest. 1993, 91: 759-765. 10.1172/JCI116294.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    D’Ettorre G, Ceccarelli G, Carnevalini M, Forcina G, Zaffiri L, Massetti AP, Mastroianni CM, Vullo V: Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Trop. 2006, 99: 83-87. 10.1016/j.actatropica.2006.08.002.CrossRefPubMedGoogle Scholar
  30. 30.
    Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, Bastien P: Long-term monitoring of visceral leishmaniasis in patients who have AIDS. J Acquir Immune Defic Syndr. 2008, 48 (Suppl 1): 13-19. 10.1097/QAI.0b013e318166af5d.CrossRefPubMedGoogle Scholar
  31. 31.
    Kubar J, Marty P, Lelièvre A, Quaranta JF, Staccini P, Caroli-Bosc C, Le Fichoux Y: Visceral leishmaniasis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocytes counts. AIDS. 1998, 12: 2147-2153. 10.1097/00002030-199816000-00009.CrossRefPubMedGoogle Scholar
  32. 32.
    Buffet PA, Rosenthal E, Gangneux JP, Lightburne E, Couppié P, Morizot G, Lachaud L, Marty P, Dedet JP: Therapy of leishmaniasis in France: consensus on proposed guidelines. Presse Med. 2011, 40 (Suppl. 2): 173-184. 10.1016/j.lpm.2010.09.023.CrossRefPubMedGoogle Scholar
  33. 33.
    Pintado V, Lopez-Velez L: Visceral leishmaniasis associated with human immunodeficiency virus infection. Enferm Infecc Microbiol Clin. 2001, 19: 353-357. 10.1016/S0213-005X(01)72665-1.CrossRefPubMedGoogle Scholar
  34. 34.
    Cota GF, de Sousa MR, Demarqui FN, Rabello A: The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis. 2012, 6 (5): e1665-10.1371/journal.pntd.0001665.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Mary C, Faraut F, Drogoul MP, Xeridat B, Schleinitz N, Cuisenier B, Dumon H: Reference values for Leishmania infantum parasitemia in different clinical presentations: quantitative polymerase chain reaction for therapeutic monitoring and patient follow-up. Am J Trop Med Hyg. 2006, 75 (Suppl 5): 858-863.PubMedGoogle Scholar
  36. 36.
    Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, Bossi L, Germagnoli L, Lazzarin A, Uberti-Foppa C, Cinque P: Real-time assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol. 2003, 41: 5080-5084. 10.1128/JCM.41.11.5080-5084.2003.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Okwor I, Uzonna JE: The immunology of Leishmania/HIV coinfection. Immunol Res. 2013, 56: 163-171. 10.1007/s12026-013-8389-8.CrossRefPubMedGoogle Scholar
  38. 38.
    Andreani G, Lodge R, Richard D, Tremblay MG: Mechanisms of interaction between protozoan parasites and HIV. Curr Opin HIV AIDS. 2012, 7: 276-282. 10.1097/COH.0b013e32835211e9.CrossRefPubMedGoogle Scholar
  39. 39.
    Sene D, Ghillani-Dalbin P, Thibault V, Guis L, Musset L, Duhaut P, Poynard T, Piette JC, Cacoub P: Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol. 2004, 31: 2199-2206.PubMedGoogle Scholar

Copyright information

© Vassallo et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Matteo Vassallo
    • 1
  • Olivier Moranne
    • 2
    • 3
    • 4
  • Damien Ambrosetti
    • 5
  • Pierre-Yves Jeandel
    • 6
  • Christelle Pomares
    • 7
  • Elisabeth Cassuto
    • 2
  • Annick Boscagli
    • 1
  • Guillaume Giraud
    • 1
  • Nathalie Montagne
    • 1
  • Chiara Dentone
    • 8
  • Ilaria Demacina
    • 8
  • Barbara Villaggio
    • 9
  • Giovanni Secondo
    • 8
  • Giuseppe Ferrea
    • 8
  • Corinne Passeron
    • 10
  • Laurence Saudes
    • 1
  • Regis Kaphan
    • 1
  • Pierre Marty
    • 7
  • Eric Rosenthal
    • 6
  1. 1.Department of Internal MedicineCannes General HospitalCannesFrance
  2. 2.Department of Nephrology, Dialysis and TransplantationNice University HospitalNiceFrance
  3. 3.Department of Public HealthNice University HospitalNiceFrance
  4. 4.Laboratory of Human Motricity, Education and Health (LAMHESS)University of Nice Sophia-AntipolisNiceFrance
  5. 5.Department of HistopathologyNice University HospitalNiceFrance
  6. 6.Department of Internal MedicineNice University HospitalNiceFrance
  7. 7.Parasitology and Mycology, Nice University Hospital and Inserm U 1065, Nice-Sophia Antipolis University, Equipe 6Centre Méditerranéen de Médicine MoléculaireNiceFrance
  8. 8.Department of Infectious DiseasesSanremo General HospitalSanremoItaly
  9. 9.Department of HistopathologyGenoa University HospitalGenoaItaly
  10. 10.Department of NephrologyCannes General HospitalCannesFrance

Personalised recommendations